Related Experiment Videos
Strategy for achieving selective killing of carcinomas
R I Garver1, K T Goldsmith, B Rodu
1Division of Pulmonary and Critical Care Medicine, UAB School of Medicine 35294, USA.
Gene Therapy
|January 1, 1994
Summary
Molecular chemotherapy using the secretory leukoprotease inhibitor (SLPI) gene shows promise. This approach selectively targets carcinomas expressing SLPI, reducing tumor cells with a specific toxin gene therapy.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- Carcinomas, cancers from epithelial cells, often resist conventional chemotherapy.
- Targeted gene expression (molecular chemotherapy) offers potential advantages.
- Developing methods for selective toxin gene expression in carcinomas is crucial.
Purpose of the Study:
- To investigate the use of transcriptional regulatory sequences from a carcinoma-expressed gene to direct toxin gene expression.
- To construct a chimeric gene utilizing SLPI regulatory sequences to drive HSVtk expression.
Main Methods:
- Identified the secretory leukoprotease inhibitor (SLPI) gene as expressed in multiple carcinomas (lung, breast, oropharyngeal, bladder, endometrial, ovarian, colorectal).
- Isolated tissue-specific SLPI transcriptional regulatory sequences.
- Constructed a chimeric gene directing HSVtk expression via SLPI sequences.
- Administered SLPI-directed toxin plasmid plus ganciclovir to SLPI-expressing and non-expressing cell lines.
Main Results:
- Transduction of the SLPI-directed toxin plasmid plus ganciclovir reduced the number of SLPI-expressing carcinomas.
- The same treatment had no effect on cell lines lacking SLPI expression.
- Demonstrated selective toxicity towards carcinomas expressing SLPI.
Conclusions:
- SLPI-directed therapeutic genes show potential for targeted toxicity in carcinoma tissues.
- This approach may be enhanced when combined with other cancer targeting strategies.
- Molecular chemotherapy using SLPI offers a promising avenue for treating specific carcinomas.